BioNTech präsentiert auf der ASCO-Jahrestagung 2024 klinische Daten-Updates zu innovativen Immuntherapie-Kandidaten
May 21, 2024 06:45 ET
|
BioNTech SE
MAINZ, Deutschland, 21. Mai 2024 – BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird auf der diesjährigen Jahrestagung der American Society of Clinical Oncology („ASCO“), die vom 31....
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
May 21, 2024 06:45 ET
|
BioNTech SE
MAINZ, Germany, May 21, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected programs from the Company’s diversified immuno-oncology pipeline at...
FDA grants Breakthrough Therapy Designation to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
May 21, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the...
Aktionärinnen und Aktionäre stimmen auf der ordentlichen Hauptversammlung 2024 der BioNTech SE allen Tagesordnungspunkten zu
May 17, 2024 11:15 ET
|
BioNTech SE
MAINZ, Deutschland, 17. Mai 2024 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) hat heute, am 17. Mai 2024, die diesjährige ordentliche Hauptversammlung abgehalten....
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
May 17, 2024 11:15 ET
|
BioNTech SE
MAINZ, Germany, May 17, 2024 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech” or the “Company”) held its Annual General Meeting (“AGM”) today, May 17, 2024. A total of 87.51 per cent of the...
Non Hodgkin Lymphoma (NHL) Global Market Report 2024: Asia-Pacific Set for Swift Growth Amidst Advancements in Immunotherapy and Diagnostic Tools
May 17, 2024 04:02 ET
|
Research and Markets
Dublin, May 17, 2024 (GLOBE NEWSWIRE) -- The "Non Hodgkin Lymphoma (NHL) Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The non hodgkin lymphoma (nhl) market...
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase I results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity
May 16, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
Over 24 weeks, a once-weekly subcutaneous injection of CT-388 achieved a clinically meaningful and statistically significant mean placebo-adjusted weight loss of 18.8% (p < 0.001) At week 24, 100%...
JAK Inhibitor Market to Register Immense Growth by 2034, Predicts DelveInsight | Key Companies - Eli Lilly and Company, Incyte Corporation, Dompé Farmaceutici S.p.A, Sanofi, Celgene, AstraZeneca, Karyopharm Therapeutics
May 15, 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, May 15, 2024 (GLOBE NEWSWIRE) -- JAK Inhibitor Market to Register Immense Growth by 2034, Predicts DelveInsight | Key Companies - Eli Lilly and Company, Incyte Corporation, Dompé...
Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update
May 15, 2024 08:05 ET
|
Third Harmonic Bio
U.S. FDA clears Investigational New Drug application for THB335 Phase 1 SAD/MAD clinical trial initiated and subject screening underway, with results expected during 1H’25 Strengthened leadership...
Roche announces FDA approval of one of the first HPV self-collection solutions in the U.S., expanding access and screening options to help eliminate cervical cancer
May 15, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
More than half of all U.S. cervical cancer patients are underscreened1, which makes reducing barriers to sample collection and increasing access to screenings crucial to ultimately helping eliminate...